= 0.03) correlation between the change in height velocity Z score and the degree of nitrogen retention to acute challenge with growth hormone, but this correlation was too weak ( r = 0.37) to be of practical value in predicting the treatment growth response in an individual child. (Pediatr Res 28: 394-400, 1990) Abbreviations rhGH, recombinant human growth hormone ANOVA, analysis of variance IRMA, immunoradiometric assay there is an increasing need for alternative ways of assessing the physiologic adequacy of a child's growth hormone secretion.
Protein accretion is the sine qua non for growth, and pituitary extracts rich in growth hormone have been known for more than half a century to produce nitrogen retention (10) (11) (12) . For this reason, before the availability of a growth hormone RIA, improvement in nitrogen balance after growth hormone administration was used routinely for diagnosis of growth hormone deficiency and for assessment of therapeutic response (1 3-22) . Even after the measurement of plasma growth hormone concentration became practical, testing the subject's nitrogen retention response to growth hormone administration remained a clinical and investigative tool (23) (24) (25) (26) (27) (28) (29) (30) (31) (32) (33) (34) (35) (36) (37) (38) .
I5N-labeled amino acids have been used extensively to measure total body nitrogen kinetics in adults and children (39) . Unlike classical nitrogen balance studies, studies using I5N-amino acids can be completed in days or, under certain circumstances (40) , hours. In addition, with appropriate models, the tracer data allow calculation of whole body protein flux, synthesis, and catabolism, rather than simply net nitrogen balance. Small numbers of short children with growth hormone deficiency have been studied with I5N techniques in the past (41, 42) . More recently, Zachmann et al. (43) used the I5N-retention test to show the biologic equivalency of recombinant and pituitary-derived hGH preparations.
Furthermore, Richter et al. (44) reported that the degree of retention of a tracer dose of ['5N]glycine induced by growth hormone administration allowed differentiation of children with normal growth hormone secretion from those with complete or partial growth hormone deficiency.
For the above reasons, we postulated that a functional test of growth hormone effect on nitrogen kinetics may provide an index of growth hormone adequacy in short children and, perhaps, predict the response to long-term growth hormone therapy. The results of the test of this hypothesis are described below. A preliminary report of this study (45) and the IGF-I gene characterization (46) have appeared previously.
It is now abundantly clear that some short children whose MATERIALS AND METHODS growth hormone secretion is regarded as mrmal after ProvocaSubjects. Thirty-seven prepubertal children between the ages tive stimulation will augment their height velocity significantly 6 and 14 and more than two SD below the mean height for when treated with exogenous growth hormone (1-9). One impli-age ,,,,ited from the Washington University Pediatric cation of these data is that these children have dysfunctional ~n d o c~n o l o g y Clinic. Their characteristics are summarized in regulation of growth hormone secretion under physiologic Table 1 . Chronic underlying medical illnesses were excluded by ditions that is masked by pharmacologic provocation. Thus, history and appropriate conventional diagnostic testing when formal enrollment in the study described below. Informed consent was obtained from all families according to procedures approved by the Washington University Human Studies Committee.
Analytical methods. Plasma growth hormone concentrations were quantified by conventional polyclonal RIA, by IM-9 lymphocyte (47) or human liver radioreceptor assay (48) , and by two-site monoclonal IRMA (Hybridtech, San Diego, CA). Serum growth hormone binding protein (49) and circulating IGF-I concentration (50) were measured as described previously. Osteocalcin was measured by specific RIA using a commercial antibody (Incstar Corp., Stillwater, MN).
In all subjects, high mol wt chromosomal DNA was isolated from nuclei of peripheral blood cells by standard methods (5 1). DNA (10 pg) was digested individually with restriction endonucleases BamHI, EcoRI, and HindIII, followed by electrophoresis and transfer to nitrocellulose or nylon membranes as described (52) . Prehybridization of the membranes, hybridization to a 32P-labeled (53) hGH cDNA probe (Genentech, Inc., South San Francisco, CA) and posthybridization washes followed the protocol of Wahl et al. (54) . Hybridization bands were detected by autoradiography at -80°C using DuPont Lightening Plus intensifying screens and Kodak XAR5 x-ray film. In addition, each child's IGF-I gene was examined as described (46) and the results have been reported in detail earlier (46) . A 2-mm punch biopsy specimen of skin was obtained from 34 of the 37 children for assessment of cultured fibroblast aminoisobutyric acid uptake response to recombinant human IGF-I according to methods detailed previously (55) .
Plasma glucose was determined by a glucose oxidase method using the Beckman glucose analyzer, and plasma insulin (56) and urinary C-peptide (57) were measured by polyclonal RIA as described previously. Urinary creatinine, urea, and ammonia were measured by standard methods (40) using commercial kits (Sigma Diagnostics, St. Louis, MO) and urinary total nitrogen was quantified by chemiluminescence using a nitrogen analyzer (Antek Instruments, Houston, TX). I5N enrichment in urinary total nitrogen, urea, and ammonia were determined by dualinlet, dual-collector isotope ratio mass spectrometry according to classical methods (40, 58, 59) .
Procedural methods. Before participation in the kinetic study and treatment protocol below, analyses of growth hormone binding protein and the growth hormone and IGF-I genes were carried out in each subject as described above. Plasma growth hormone responses to oral clonidine (5 &kg) and i.v. insulin (0.1 U/kg) provocation were measured in the overnight postabsorptive state. The circulating growth hormone concentration was quantified by polyclonal RIA in all samples. In each provocative test, the two plasma samples in which growth hormone concentration was the highest when measured by polyclonal RIA were remeasured by monoclonal IRMA or by IM-9 or human liver radioreceptor assays as described above.
Nitrogen kinetics. Subsequently, each child was admitted to the Washington University Pediatric Clinical Research Center for 9 d to study the acute effects of growth hormone administration on nitrogen kinetics. According to a prescription provided by the research dietitian after a diet history, each subject consumed an isocaloric diet containing 1 g of protein per kg body wt daily for the week before admission. This procedure was intended to minimize changes in dietary protein intake on admission, when a fully monitored diet containing the same dietary energy and protein intakes was consumed for the entire 9-d hospitalization.
During the hospitalization, blood was drawn each morning in the postabsorptive state and assayed for glucose, insulin, IGF-I, and, on the 4th and 9th days, for osteocalcin as described above. All urine was collected, acidified, and frozen in 8-h aliquots for later analysis of urinary nitrogen end-products and their 15N enrichments as noted above. On the 2nd and 6th hospital days, a dose of mixed I5N-labeled amino acids (1 mg I5N/kg body wt) was administered orally with breakfast. The composition of the mixture (mg amino acid/kg body wt) was as follows: leucine 1.007; valine 0.90 1; methionine 0.306; phenylalanine 0.806; lysine 1.007; alanine 0.606; aspartic acid 0.701; glutamic acid 0.806; glycine 1.007; serine 0.507; and tyrosine 0.40 1.
From the morning of the 5th day until discharge rhGH (Humatrope, Eli Lilly Co., Indianapolis, IN) was injected S.C. every 12 h at the dose of 16 pg/kg body wt. Urine samples collected for 72 h as above for nitrogen content and isotopic enrichment on the 2nd, 3rd, and 4th, and on the 6th, 7th, and 8th hospital days will be referred to subsequently as the pre-and post-growth hormone samples, respectively.
Growth response. On discharge from the hospital, each child was treated with rhGH (Humatrope) at the dose of 75 &kg body wt given three times weekly by S.C. injection. At three monthly intervals over the ensuing 6 to 12 mo, each child was reexamined and his/her height measured with a Harpenden stadiometer. If a child failed to exceed his/her pretreatment height velocity by at least 2 cm/y at the 6-mo visit, growth hormone therapy was discontinued. Final examination and height measurement were performed in the remaining "responders" at the 12-mo visit.
Calculations. Total I5N in each urine sample was calculated as the product of the I5N enrichment and the total nitrogen content. Cumulative I5N excretion was the sum of the total urinary I5N excretion in the pre-and post-growth hormone samples obtained over the 72 h after administration of the tracer dose. Similarly, cumulative 72-h [I5N]urea excretion was calculated from the urinary [I5N]urea enrichment and the urinary urea nitrogen content in each sample. Whole body nitrogen and protein kinetic parameters were calculated using established expressions according to the classical, single nitrogen pool model (39) .
Values are reported as mean f SD. Overall statistical comparisons were made by ANOVA with t test for paired analyses used when appropriate. Correlations were calculated by univariate linear regression.
RESULTS
Clinical characteristics. The clinical characteristics of the subjects are shown in Table I . By design, all were prepubertal with a mean age of 8.7 k 2.7 (SD) y and height Z score of -3.0 k 0.7. On the average, bone age was delayed by slightly more than 2 y and the group, as a whole, had parents whose average heights were shorter than the 50th percentile height for normally sized adults.
Plasma growth hormone. Twenty-six of the 37 children had a peak plasma growth hormone response of greater than 10 ng/ mL to insulin and/or clonidine provocation. Eight had a peak plasma growth hormone value greater than 7 but less than 10 ng/mL to one test but less than 7 ng/mL to the other test. Three of these eight children had plasma growth hormone values of greater than 10 ng/mL measured during sleep. Three additional children had peak plasma growth hormone responses less than 7 ng/mL to both clonidine and insulin challenge and were classified as growth hormone deficient. None of the latter three had hormonal evidence of additional TSH or ACTH deficiency. Because the subsequent responses of the growth hormone-deficient children to acute and chronic growth hormone supplementation were indistinguishable from those of the remaining 34 subjects, the results for the growth hormone-deficient children will be included with those of the study group as a whole but identified individually when appropriate.
Of the 34 non-growth hormone-deficient subjects, none had a clearly abnormal circulating growth hormone molecule estimated from the ratio of radioreceptor or of monoclonal IRMA assayable growth hormone to the value obtained using conventional polyclonal RIA (45) . Thus, the average radioreceptor assay/RIA and IRMAIRIA plasma growth hormone ratios in the selected samples described earlier were 0.97 + 0.28 (SD) and 0.88 + 0.22, respectively, with no value below 0.5, the 5th percentile ratio found in subjects of normal height. Similarly, no subject had absent serum growth hormone binding protein (47) .
Growth hormone and IGF-I genes. The growth hormone gene locus was analyzed in all 37 subjects and in 10 controls of normal stature by hybridization of a 32P-labeled hGH cDNA to chromosomal DNA digested with three restriction enzymes as described in Methods. A representative autoradiograph of BamHIdigested DNA from eight subjects is illustrated in Figure 1 . As indicated, all five genes within the 48-kb cluster are visualized and appear normal in length (53) . A similar normal pattern was observed in all subjects with each restriction enzyme. Additionally, the present group of 37 children was included in a previous report of 61 short children who were evaluated for mutations in the IGF-I gene (46) . Analysis of chromosomal DNA from these children failed to reveal any variation in the IGF-I gene except for a Hind111 site polymorphism present in normally sized individuals as we11 (46) .
Fibroblast responsiveness to ZGF-I. All 34 fibroblast cell lines tested for aminoisobutyric uptake response to challenge with recombinant human IGF-I (55) responded normally with a mean ED50 value of 2.41 f 0.7 1 ng/mL and a 2.50 + 0.40-fold maximal stimulation of uptake (55) .
Nitrogen kinetic response. Daily total urinary nitrogen excretion declined slightly but significantly ( p < 0.05 by ANOVA)
between the 1st and 2nd days of hospitalization (Fig. 2) but remained unchanged from the 2nd through the 4th days. Growth hormone injections, begun on the 5th hospital day, induced a second decline in urinary total nitrogen, which achieved a new constant level on d 6 through 8 (Fig. 2) . There was no change in the excretion ratios of urea or ammonia to total nitrogen, and creatinine excretion remained unchanged throughout the hospitalization (data not shown).
The total cumulative excretion of I5N after the first tracer dose Fig. 1 . Analysis of the growth hormone locus in chromosomal DNA from eight short subjects. DNA was digested with BamHI; electrophoresis, transfer to a nylon membrane, and hybridization of3'P-hGH cDNA were performed as described in Methods. Fragment sizes (kb) and the gene contained within each detected fragment are indicated. (72 h pre-growth hormone urines) was compared with the cumulative "N excretion of the second tracer dose during 72 h of S.C. growth hormone administration at the dose of 16 g per kg body wt every 12 h (post-growth hormone urines). Before the administration of growth hormone, cumulative I5N excretion averaged 20.3% of the dose. During acute supplementation with exogenous growth hormone, I5N excretion declined an average ever, daily urinary C-peptide excretion (Fig. 5b ) rose significantly of 3 1 + lo%, but the change varied considerably between sub-( p < 0.05) within 24 h of growth hormone administration and jects, ranging from a 5.7 to a 50.5% decrease (Fig. 3) . The three stayed elevated throughout the remaining period of growth horgrowth hormone-deficient children diminished their ISN excre-mone treatment. Serum osteocalcin was 1 1.8 +. 2.0 ng/mL before tions by 3 1.5, 3 1.8, and 50.5%. ANOVA showed no statistically growth hormone supplementation and remained unchanged significant relationships between the subjects' clinical character-after 4 d of rhGH injections. In no individual was there a istics, bone age delay, and IGF-I level and the degree of nitrogen substantial change in serum osteocalcin. retention after growth hormone administration.
Growth response. Of the 37 subjects who had their nitrogen Figure 4 shows the results of whole body protein kinetic kinetic responses measured, one dropped out of the study before parameters calculated from the urinary total nitrogen and total the 3-mo visit and one voluntarily discontinued follow-up at 9 I5N-excretion data as described (39) . Before growth hormone mo of therapy. Data from these two subjects are excluded from treatment, whole body protein turnover, synthesis, and catabo-discussion of long-term response to growth hormone treatment. lism were 4.38 a 0.56, 3.52 + 0.60, and 3.38 + 0.5 g.kg-'.d-], At the 6-mo treatment visit, growth hormone treatment of three respectively. Growth hormone challenge increased body protein children was discontinued because their height velocities had not turnover by enhancing both protein synthesis and protein break-increased by more than 2 cm/y above their pretreatment height down (Fig. 41 , but because synthesis increased more than break-velocity values. The complement of this observation is that 33 down, net body protein accretion (synthesis minus catabolism) of the 36 individuals who were treated with growth hormone for increased by more than 200% from 0.14 + 0.03 to 0.35 + 0.02 6 mo grew at an accelerated rate. Of the 32 children who g. kg-' .d-I ( p < 0.001).
completed a full year of treatment, two girls developed breast Growth hormone challenge at 16 ~g / k g every 12 h caused an buds by 1 y of therapy. Their data are included in subsequent increase in the ~o s t a b s o~t i v e serum IGF-I level from a Pre-analyses because pubertal progression was minimal and exclusion growth hormone value of 0.56 0.48 to 0.97 * 0.56 U/mL by of their data had no effect on the statistical analyses that follow.
the morning of the 4th day of treatment, significant at the P < NO adverse effects were detected during the prolonged growth 0.05 level by ANOVA. By similar analysis, there Was no relation-hormone treatment. We observed no significant changes in postship between any of the whole body protein kinetic indices absorptive blood glucose, cholesterol, or triglyceride values measderived from the ISN-tracer data and the change in circulating ured by routine clinical chemistry assays. ~h~~~ was no signifi-IGF-I. The acute 4-d treatment with rhGH caused no change in cant rise in antibody titers to ~~~h~~i~h i~ coli proteins or to circulating growth hormone binding protein and no significant growth hormone as measured by the standardized assays at the change was observed in fasting plasma glucose or insulin values Eli Lilly Company. (Fig. 5a ) during the period of growth hormone challenge. Table 1 shows the growth parameters for the 32 children at the end of a year's treatment with rhGH at the dose of 75 @/kg bone age to the change in chronologic age averaged 1.3 + 0.8, a Fig. 3 , Distribution of the percent change in excretion of the mixed value not statistically different from 1.0 by t test. Predicted adult 'SN amino acid tracer dose by the study subjects during 72 h of growth height increased, but not significantly (Table 1) . Neither pretreathormone treatment. ment IGF-I nor the acute change in IGF-I to growth hormone challenge predicted the long-term growth response. Only a low pretreatment height velocity correlated significantly with the change in annualized growth rate at 1 y of treatment (r = -0.6, p < 0.001).
Neither the measured growth rates nor the increments in height velocity above pretreatment values (when expressed in absolute terms of cm/y) at 3, 6, or 12 mo of therapy were correlated with any of the indices of protein dynamics derived from the I5N data, including the percent change in 15N excretion itself. Figure 6 shows the relationships between the change in "N retention induced by the acute growth hormone challenge and the increment above pretreatment height velocity measured after 1 y of treatment with rhGH. When the change in height velocity measured after 1 y of rhGH treatment was expressed as a Z score to normalize for age-related differences in growth rate, there was a weak but significant correlation (r = 0.37, p = 0.03) with the change in l5N retention to the acute growth hormone challenge Fig. 4 . Whole body protein turnover, synthesis, breakdown, and net (Fig. 6) . Obviously, for an individual subject, this relationship protein accretion (synthesis minus breakdown) in the study subjects was too weak to be predictive of height velocity response to before and during 72 h of growth hormone treatment.
growth hormone treatment. Fig. 6 . Relationship between the change in nitrogen retention to an acute challenge with growth hormone and the change in ht velocity at the end of I y of treatment with rhGH, expressed as change in height velocity Z score for age. This relationship is defined by the equation y = 0 . 1 5~ + 1.4 (r = 0.37) and is significant at the p = 0.03 level.
CHANGE IN '5N RETENTION (%)

DISCUSSION
In our study, the acute metabolic response to growth hormone was tested in a group of 34 short children whose growth hormone secretion was normal after challenge with conventional provocative stimuli and three children who met the classical criteria of growth hormone deficiency. Subsequently, all were treated with rhGH for 6 mo to 1 yr. Thirty-two children completed a year's therapy.
The study population was well characterized. In addition to conventional clinical assessment and routine measurements of bone age, growth hormone secretion, and circulating IGF-I, the subjects' growth hormone and IGF-I genes (46) were shown to be normal. There was no gross structural abnormality of the circulating growth hormone molecule as probed by radioreceptor and monoclonal antibody assays (47, 48) . No child had absent growth hormone receptors as assessed by assaying circulating growth hormone binding protein levels (49) . Each subject's cultured fibroblasts were normally sensitive to IGF-I with regard to uptake of aminoisobutyric acid (55) .
As in other reports (1-9), we showed that a significant percentage of children who had apparently normal growth hormone secretion will augment their height velocity significantly when treated with exogenous growth hormone. Thirty-three of the 36 subjects treated for 6 mo grew at a height velocity 2.0 cm/y or more greater than their pretreatment rate. Of the 32 subjects completing a year of growth hormone treatment, 29 had grown a measured annual height velocity of 2.0 cm or more faster than the pretreatment rate and half grew 3.0 cm or more faster than their pretreatment height velocity. On average, the children's height velocity was 77% faster after 1 y of treatment with rhGH, 8.3 + 1.6 versus 4.7 k 1.2 cm/y (Table 1) . These results are similar to previous studies in other groups (7) (8) (9) . Consistent with the reports of others (7, 8) , and except for the inverse correlation with the child's pretreatment height velocity also shown by Lin et al. (7) , we were unable to find any correlation between anthropometric parameters, bone age, or circulating growth hormone levels achieved after provocative testing and subsequent growth response to treatment. In contrast to the largest study reported to date (8), we were also unable to find a relationship between the child's pretreatment serum IGF-I concentration and subsequent growth response to treatment or to calculate significantly improved prediction of final adult height. Others have also failed to find the former relationship (7) or the latter apparent improvement (9) . Nor did we find a relationship between the acute changes in serum IGF-I and subsequent growth, consistent with the data of Gertner et al. (4) .
In an attempt to provide a more physiologic predictor of growth response to chronic growth hormone treatment, we assessed the child's nitrogen retention response to an acute challenge with growth hormone and quantified whole body nitrogen and protein kinetics using I5N-labeled amino acids. The former approach is not new but the latter method has been little used (41) (42) (43) (44) . Its potential advantages are several. In particular, however, is the advantage that addition of the tracer allows one to distinguish between an increase in protein synthesis and a decrease in protein breakdown as the mechanism of reduced nitrogen excretion after growth hormone administration. For this purpose, we used a mixture of I5N-labeled essential and nonessential amino acids rather than the more commonly used [lSN] glycine in an attempt to label the nitrogen pool more uniformly. Because glycine constitutes about % the composition of collagen, collagen itself represents about 20-25 % of total body protein, and growth hormone's effects on collagen (60) might not reflect its actions on body protein synthesis as a whole, we elected to avoid potential bias introduced by using this amino acid singly as a tracer.
On the average, growth hormone enhanced "N retention by 3 1 %, but the variability in the nitrogen response to rhGH was striking (range 5.7-50.5%) considering that the subjects were on the same reasonably constant dietary protein intake for 8 d before the first tracer study. Richter et al. (44) found a similar variability using ['5N]glycine tracer. However, in contrast to Richter et al. (44) , we were unable to find a relationship between a child's growth hormone status determined with provocative testing and the child's ''N retention after growth hormone challenge. Thus, for example, two of the three children who failed both growth hormone provocative tests had ''N retention responses virtually identical to the mean value. This result is also decidedly different from several earlier studies (23, 25, 27, 29, 30, 32, 6 I ) where children with growth hormone deficiency had distinctly greater reductions in urinary nitrogen excretion than children who were not deficient in this hormone.
The "N tracer allowed us to show for the first time in a large, well-defined group of short children that the growth hormoneinduced decrease in nitrogen excretion is not the result of decreased protein breakdown. Body protein breakdown, in fact, increased, but less so than synthesis. Thus, there was a net anabolic effect. Presumably, the increase in body protein breakdown reflects the necessary remolding of body structural proteins necessary for growth. These data complement the recent report of Dahms et al. (62) who showed, under similar circumstances in a group of growth hormone-deficient children, that growth hormone administration produced a decrease in urea synthesis. Because the latter authors concluded that the decline in urea production reflected decreased production of ureogenic substrates by peripheral tissues, we might postulate that the increased amino acid supply generated via augmented protein breakdown found in our study is reused locally for protein synthesis.
All of our subjects underwent a therapeutic trial with rhGH at a dose of 75 pg/kg given three times a week. There are limited systematic data available on growth hormone secretory rates in childhood. Based on the recently published data of AlbertssonWikland et al. (63) , the growth hormone treatment doses used in our study were within the normal secretory range for children of the same height and pubertal status. Based on similar data recently reported by Rosenbaum and Gertner (64) , the treatment dose used in our study may have been as high as three times the child's usual secretory rate.
The response to therapy was highly variable with the change in height Z score ranging from 0 to +1.6 after 1 y of treatment with rhGH. The two children with the greatest increase in nitrogen retention had the greatest increment in height velocity Z score at 1 y (Fig. 6 ). All seven children whose height velocity Z scores increased by more than 6 had a greater than 25% decline in I5N excretion. The two children with decrements in I5N excretion less than 10% increased their growth rate Z score by less than 4. On the other hand, most children showed a greater than 25% decrease in "N excretion but increased their height velocity Z scores by less than 4 (Fig. 6) . Thus, overall, the weak but significant correlation demonstrated between "N retention and height velocity Z score is not a useful predictor of height velocity response for individual subjects.
There may be several reasons for the lack of demonstrated correlation. First, the children received a fixed dose of growth hormone for the acute challenge. Based on the recently reported growth hormone secretion rates mentioned above (63, 64) , this dose may have represented a variable stimulus to nitrogen retention depending on the magnitude of the child's own prior endogenous secretory rate. Similarly, growth hormone may have induced a variable degree of insulin resistance, both with regard to its effects on amino acid metabolism and in reference to its role in carbohydrate homeostasis. The almost immediate increase seen in urinary C-peptide excretion supports the rapid development of some decline in tissue sensitivity to insulin. On the other hand, it is likely that more long-term adaptive and accommodative changes in fuel metabolism induced by chronic growth hormone treatment superceded any temporary acute effects of growth hormone on nitrogen kinetics. In addition to alterations in insulin sensitivity mentioned above, these include alterations in energy intake and/or expenditure, as well as peripheral adipose tissue lipolysis. Only serial studies of the kinetics of amino acid, glucose, and lipid fuels before and during growth hormone supplementation can help resolve these issues.
In conclusion, 37 short children exhibited dramatic but highly variable changes in body protein kinetics in response to a short course of growth hormone that increased whole body protein turnover, synthesis, and breakdown. The growth rate increments in response to long-term growth hormone treatment were also variable and were not predictable from the acute nitrogen kinetic changes induced by growth hormone administration. Presumably, this variability is due to physiologic mechanisms that regulate body nitrogen economy during growth. Understanding the mechanisms responsible for the variability will provide insight into the relationships between metabolic fuel transport, energy balance, and protein dynamics and their regulation by growth hormone in growing children.
